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luconazole (Diflucan(R), Roerig, New York, NY)
was recently developed for the treatment of sys-
temic and surface fungal infections. It is an azole
in the same family as ketoconazole and itraconazole.
Fluconazole has several advantages over the other
antifungal drugs including the option of oral ther-
apy. The side-effect profile is minimal. Studies
have shown it to be efficacious for the treament of
vaginal yeast infections in a single oral dose.
STRUCTURE AND DERIVATION
Fluconazole [(difluoro-2,4-phenyl)-2-bis((1H-tri-
azole-l,2)-4-yl-1)-l,3-propanol-2] is an azole anti-
fungal agent. The imidazole, i.e., ketoconazole, has
been modified by the replacement of the imidazole
ring with a triazole ring, addition of a second triazole
ring, and substitution of a difluorophenyl moiety
for a dichlorophenyl moiety. These changes provide
more selective inhibition offungal enzyme systems,
greater metabolic stability, and enhanced water sol-
ubility.
MECHANISM OF ACTION
Fluconazole interferes with the cytochrome P-450-
dependent enzyme C-14a-demethylase, which is
responsible for production of ergosterol, the major
component of the fungal cell membrane. The dis-
ruption of ergosterol synthesis causes structural and
functional changes in the membrane which predis-
pose the fungus to osmotic and immune-mediated
damage and interfere with cell adherence, The
triazole derivatives bind to the cytochrome P-450
enzyme with greater specificity than their pred-
ecessors. Additional antifungal activity may be
accounted for by the azole inhibition of cyto-
chrome c oxidative and peroxidative enzymes, lead-
ing to increased intracellular peroxidase.
3-s
PHARMACOKINETICS
Fluconazole is water-soluble and thus is readily ab-
sorbed from the gastrointestinal tract. The peak
plasma concentration in humans, which is reached
2 h after dosing, is 2.44-3.58 Ig/ml after a 150-mg
dose. The presence of food does not affect the
absorption of fluconazole but delays the time to
maximum serum concentration until 4 h after dos-
ing. The bioavailability of fluconazole is not af-
fected by gastric pH. 7,s The amount of fluconazole
absorbed is linearly proportional to the dose, and
urinary excretion data indicate that the oral bioavail-
ability of fluconazole is 80-90%.
Fluconazole has a volume of distribution that
closely approximates total body water, 0.6-0.8 1/kg.
Roughly 10% of fluconazole is protein-bound in
humans. This low degree of binding facilitates the
transfer of the drug into the central nervous system
regardless of the presence of inflammation of the
meninges,
mq2 Penetration of the drug into the
skin and nails has been demonstrated in humans.
3
Houang et al. found fluconazole to be persistent
in vaginal secretions with concentrations above the
MIC for Candida a/bicans for at least 72 h after a
single 150-mg oral dose.
Very little metabolism of fluconazole occurs; the
vast majority of it is eliminated intact through the
kidney. Humphrey et al. detected 3 metabolites
of fluconazole in the urine of treated dogs and mice,
but they comprised only 4% of the total adminis-
tered drug. Two primary mechanisms influence the
elimination. First, the drug is rapidly filtered as
a result of the small amount of protein binding.
Fluconazole is then extensively reabsorbed by the
tubules, explaining its long half-life.4
Caution must be exercised in the administration
of fluconazole to patients with impaired renal func-
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tion. Several authors have reported a positive corre-
lation of the drug half-life with decreasing renal
function. 15 In patients with normal renal function,
the half-life is 31 h. This half-life is increased to
98 h in patients with creatinine clearances of <20
ml/min. The manufacturer, therefore, recommends
a decreased dose in patients with renal insuffi-
ciency.
SIDE EFFECTS AND INTERACTIONS
The side-effect profile of fluconazole is favorable.
Only 8.9% of the patients treated with a single 150-
mg oral dose experienced adverse effects consid-
ered to be "possibly related" or "definitely related"
to the drug.
16 The most common complaint was
nausea (3.3%), followed by headache (1.2%), ab-
dominal pain (0.8%), dizziness (0.7%), and heart-
burn or indigestion (0.7%). The adverse effects out-
weighed the benefit oftreatment in 0.1% of patients
receiving the single dose.
6
Asymptomatic elevations of the liver transami-
nases have been reported in approximately 3% of
individuals receiving treatment. 17 Rare fatal cases
of Stevens-Johnson syndrome
18 and hepatic failure 19
have been reported in patients using fluconazole.
Because of the negligible level of hepatic metab-
olism, fluconazole would be expected to have fewer
drug interactions than its azole predecessors. In a
study of 18 healthy male volunteers, the concomi-
tant administration of fluconazole and rifampin re-
suited in a 22% decrease in fluconazole’s half-life,e
These data suggest that the dose of fluconazole
should be increased in those patients receiving
both drugs.
The cyclosporin concentrations were signifi-
cantly increased in renal transplant patients who
were also treated with daily fluconazole. Torregrosa
et al.z observed 3 patients who required at least a
50% reduction in cyclosporin dosing to maintain
therapeutic concentrations. Lazar and Wilner,zz
however, found no statistically significant changes
in cyclosporin plasma concentrations in bone-mar-
row transplant patients who were given single or
multiple doses of fluconazole in addition to their
stable doses of cyclosporin. These differences may
occur due to the renal elimination of fluconazole.
It would seem prudent to monitor cyclosporin levels
in patients receiving both drugs.
The coadministration of fluconazole and tolbuta-
mide resulted in a significant increase in the mean
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serum concentration oftolbutamide, zz The adminis-
tration of fluconazole has also been noted to cause
an increase in serum concentrations of theophyl-
line. z3
A prolongation of the prothrombin time was ob-
served in healthy volunteers receiving both warfarin
and fluconazole,ze This increase in warfarin activity
may necessitate changes in the anticoagulant dose.
Similarly, patients receiving both phenytoin and
fluconazole were noted to have a significantly in-
creased area under the curve (AUC) for phe-
nytoin.ZZ,z4
Lazar and Wilnerzz found the pharmacokinetics
of oral contraceptives to be unaffected clinically
by the administration of fluconazole. Fluconazole
is considered a pregnancy category C drug by the
FDA; however, Inman and colleagueszs found no
demonstrably harmful effect on pregnancy or its
outcome.
SPECTRUM OF ANTIFUNGAL ACTIVITY
Fluconazole is effective in the treatment of both
superficial and invasive fungal infections. There is
a poor correlation between in vitro and in vivo azole
activity against many fungal pathogens. Therefore,
for the evaluation of the effectiveness of flucona-
zole, animal models have been used. Susceptible
conditions incl,ude aspergillosis,
26 coccidioidomyco-
sis,z7 histoplasmosis,
z8-3 cryptococcosis,
z6 blastomy-
cosis,z9 systemic phaeohyphomycosis,
3 and candi-
diasis)2-34
CLINICAL APPLICATIONS
Multiple clinical trials have compared the efficacy
of single-dose fluconazole with topical antifungal
regimens for vaginal infections. Van Heusden and
coworkers3e conducted a multicenter trial and found
no differences in the clinical and mycological effi-
cacy between fluconazole and 500-mg intravaginal
clotrimazole. Moreover, a majority of patients pre-
ferred oral to intravaginal treatment. Osser et al.ss
compared econazole vaginal tablets with single 150-
mg oral-dose fluconazole. At the 28-35-day follow-
up, the women treated with fluconazole had a signif-
icantly higher clinical or microbiological cure rate
than those given econazole.
Sobel and colleagues
34 conducted a multicenter
study comparing the efficacy of single-dose 150-
mg oral fluconazole with 7-day 100-mg clotrimazole
vaginal tablets. At the 14-day evaluation, clinical
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TABLE I. Costs of selected antifungal agents
Drug
Cost for
Regimen total treatment
Mycelex(R) (clotrimazole)
Gynelotrimin(R) (clotrimazole)
Diflucan(R) (fluconazole)
Monistat(R) (miconazole)
Clotrimazole
Terazol(R) (terconazole)
Vaginal suppositories 7 days $9.99
Vaginal cream 7 days $13.33
Single 150-mg tablet $13.70
Three 50-mg tablets $26.25
Vaginal cream 7 days $24.72
Vaginal tablets 7 days $24.85
Vaginal suppositories 3 days $32.68
aMiles Consumer, Elkhart, IN.
bSchering, Kenilworth, NJ.
CRoerig, New York, NY.
d’eOrtho, Raritan, NJ.
cure or improvement was noted in 94% of the fluco-
nazole-treated and 97% of the clotrimazole-treated
patients. At the 35-day evaluation, 75% of both
groups remained clinically cured. Just over 50% of
each group were considered therapeutic cures. In
both treatment groups, the patients with histories
of recurrent vaginitis were significantly less likely
to respond clinically and mycologically.
COST
Table presents the retail costs to the patient.
These costs will vary depending on the geo-
graphic location.
SUMMARY
The modified structure of fluconazole gives it sev-
eral advantages over its predecessors, including
excellent oral bioavailability and an improved side-
effect profile. In a single oral dose of 150 mg, fluco-
nazole is efficacious against candidal vaginitis.
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